Regulatory updates

What is changing for supplement brands

Found daily at official sources (the Federal Register, eCFR, FDA, FTC, USP, and California’s OEHHA), summarised from the source text only and checked against it before it appears here. Every item links to the primary document; most carry a full article on what it means for a supplement brand.

Subscribe (RSS)Get these by email (free)Requirements library14 published

September 2026

InfoFDAsource dated 2026-09-04
ZUBB Dietary Supplement may be harmful due to hidden ingredient | FDA
The FDA advises consumers not to purchase or use ZUBB Dietary Supplement, a product promoted for weight loss. According to the FDA notice, it was identified during an examination of international mail shipments. FDA laboratory analysis confirmed the product contains sildenafil, the active ingredient in Viagra, not listed on the label. Sildenafil may dangerously lower blood pressure when combined with nitrates, especially for those with diabetes, high blood pressure, high cholesterol, or heart disease.
What to do
No action needed.
Read the full article Read the sourcewww.fda.govpublished 2026-09-06
InfoIndustry presssource dated 2026-08-14
FDA Deep Dive Into CGMPs
An FDA webinar on 21 CFR Part 111 product specifications offered compliance insights for dietary supplement manufacturers and document reviewers, according to industry press.
What to do
No action needed.
Read the full article Read the sourcewww.npanational.orgpublished 2026-09-05
WatchIndustry presssource dated 2026-08-11
CRN Welcomes FDA Focus on Strengthening GRAS Transparency, Calls for National Uniformity
The Council for Responsible Nutrition welcomed FDA's proposed GRAS transparency rule. CRN supports enhanced accountability for self-GRAS reviews and FDA visibility into ingredients, but warns against eliminating self-GRAS, which could stifle innovation. It proposes a GRAS ingredient registry and urges national uniformity to prevent conflicting state requirements.
What to do
Review your GRAS determinations and prepare to engage with the proposed rule through industry associations like CRN.
Read the full article Read the sourcewww.crnusa.orgpublished 2026-09-05
InfoIndustry presssource dated 2026-08-12
FDA Proposes Mandatory GRAS Notifications; Industry Weighs In
The source title indicates FDA proposed mandatory GRAS notifications, but the provided article body covers only ashwagandha health topics and does not describe any regulatory change, detail, or industry comment.
What to do
No action needed.
Read the sourcewww.wholefoodsmagazine.compublished 2026-09-05
InfoIndustry presssource dated 2026-08-11
Experts doubt whether FDA would have manpower to do GRAS reviews
An industry press article reports experts doubt FDA has the manpower to handle mandatory GRAS notifications if the proposed rule is finalized. This could affect how dietary supplement ingredient safety reviews are managed.
What to do
No action needed.
Read the sourcewww.supplysidesj.compublished 2026-09-05
InfoFDAsource dated 2026-08-26
Revival Animal Health, LLC Voluntarily Recalls Feline Milk Replacers Due to Inconsistent Levels of Vitamins and Trace Minerals
Revival Animal Health is recalling its Breeder’s Edge® and Shelter’s Choice® Feline Milk Replacers because they contain low levels of potassium, copper, folic acid, choline, and/or pyridoxine (vitamin B6). This is a pet food recall, not a human dietary supplement action.
What to do
No action needed.
Read the sourcewww.fda.govpublished 2026-09-05
InfoFDAsource dated 2026-09-03
FDA Seeks Public Input to Advance Development of Botanical Drug Products
The FDA announced a request for information seeking public input on advancing botanical drug products, according to a press announcement.
What to do
No action needed.
Read the sourcewww.fda.govpublished 2026-09-05
InfoFDAsource dated 2026-09-03
SUPPLX.com Issues Voluntary Nationwide Recall of Business Pill and Branch Manager for Men Due to Undeclared Yohimbine
SUPPLX.com is voluntarily recalling 'Business Pill' and 'Branch Manager for Men' dietary supplements marketed for male sexual enhancement. FDA laboratory analysis found the products contain undeclared yohimbine.
What to do
No action needed.
Read the sourcewww.fda.govpublished 2026-09-05
InfoOEHHAsource dated 2026-09-03
Announcement of the Carcinogen Identification Committee Meeting Scheduled for November 17, 2026
OEHHA announced a November 17, 2026 meeting where the Carcinogen Identification Committee will review whether ethoprop should remain on California's Proposition 65 list of cancer-causing chemicals, according to an OEHHA notice. A 45-day public comment period on a hazard identification document ends October 19, 2026. No submissions were received during a prior information request.
What to do
No action needed.
Read the sourceoehha.ca.govpublished 2026-09-05
InfoFederal Registersource dated 2026-09-04
Federal Register :: Advancing Development of Botanical Drug Products; Request for Information
The FDA opened a public docket (FDA-2026-N-9550) to request comments by November 3, 2026, on advancing development of botanical drug products. The agency seeks stakeholder perspectives on challenges and potential solutions in gathering information required by the FD&C Act, according to the Federal Register.
What to do
No action needed.
Read the full article Read the sourcewww.federalregister.govpublished 2026-09-04

August 2026

InfoFDAsource dated 2026-08-28
HFP Constituent Updates
The FDA announced a public meeting on March 3, 2026, regarding Dietary Supplement Innovation and the Scope of Dietary Ingredients. According to the FDA's HFP Constituent Updates, this meeting concerns dietary supplement innovation and the scope of dietary ingredients.
What to do
No action needed.
Read the full article Read the sourcewww.fda.govpublished 2026-08-29
WatchFederal Registersource dated 2026-08-11
Substances Generally Recognized as Safe
The FDA is proposing a rule to make GRAS notices mandatory, with some exceptions. It would require persons introducing a human or animal food substance under the GRAS provision to notify the FDA of their safety conclusion. The rule, if finalized, aims to increase transparency and help the FDA identify potentially unsafe substances. Comments on the proposal are due by December 9, 2026.
What to do
Submit comments on the proposed rule by December 9, 2026.
Read the full article Read the sourcewww.federalregister.govpublished 2026-08-17
WatchOEHHAsource dated 2026-06-30
Proposition 65: Omnibus 2026 Pre-Rulemaking
California OEHHA has released draft Prop 65 rule changes open for public comment. One change narrows the 'naturally occurring' exemption: a chemical extracted or concentrated from a plant can now count as human-caused even if it wasn't chemically altered — relevant if you sell botanical extracts. Other changes touch internet-purchase warnings and add QR codes as an approved warning method.
What to do
If you sell botanical-extract products or ship into California, review whether the naturally-occurring and internet-purchase/QR-code warning changes affect your labeling, and consider submitting a comment before the rulemaking is finalized.
Read the full article Read the sourceoehha.ca.govpublished 2026-08-17applies to botanical extract
InfoFederal Registersource dated 2026-02-06
Listing of Color Additives Exempt From Certification; Spirulina Extract
FDA approved wider use of spirulina extract as a color additive in foods generally, including coating formulations applied to dietary supplement tablets and capsules, and tightened the allowed limits for lead, arsenic, mercury and (new) cadmium in the ingredient.
What to do
If your tablets or capsules use a spirulina-based coloring in the coating, confirm with your contract manufacturer or ingredient supplier that the spirulina extract they use meets the new, lower heavy-metal limits.
Read the full article Read the sourcewww.federalregister.govpublished 2026-08-17

Compliant Always customers see these filtered to their own product types inside the portal, with an unread count. This page is the same list, unfiltered.

What is changing for supplement brands

September 2026

ZUBB Dietary Supplement may be harmful due to hidden ingredient | FDA

FDA Deep Dive Into CGMPs

CRN Welcomes FDA Focus on Strengthening GRAS Transparency, Calls for National Uniformity

FDA Proposes Mandatory GRAS Notifications; Industry Weighs In

Experts doubt whether FDA would have manpower to do GRAS reviews

Revival Animal Health, LLC Voluntarily Recalls Feline Milk Replacers Due to Inconsistent Levels of Vitamins and Trace Minerals

FDA Seeks Public Input to Advance Development of Botanical Drug Products

SUPPLX.com Issues Voluntary Nationwide Recall of Business Pill and Branch Manager for Men Due to Undeclared Yohimbine

Announcement of the Carcinogen Identification Committee Meeting Scheduled for November 17, 2026

Federal Register :: Advancing Development of Botanical Drug Products; Request for Information

August 2026

HFP Constituent Updates

Substances Generally Recognized as Safe

Proposition 65: Omnibus 2026 Pre-Rulemaking

Listing of Color Additives Exempt From Certification; Spirulina Extract